HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $44 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on ITeos Therapeutics (NASDAQ:ITOS) with a maintained price target of $44.
March 07, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on ITeos Therapeutics with a steady price target of $44.
The reiteration of a Buy rating and maintenance of a $44 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on ITeos Therapeutics' stock price. The analyst's continued bullish stance suggests a strong belief in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100